Pα+ Psychedelic Bulletin #187: NYT Article Reignites MDMA Rejection Blame Game; FDA “Wanted to Approve” MDMA; GH’s Data and RFK Jr. Confirmation Send Psychedelics Stocks Soaring

Earlier this week, The New York Times published a story that, above all, suggests that Psymposia was substantially to blame for FDA’s August rejection of Lykos Therapeutics’ MDMA-assisted therapy for PTSD new drug application (NDA), and that “other psychedelic drugs in the pipeline could be jeopardized.” Murmurs of the reporting had been swirling for some time and its…

Source